BriaCell Announces Phase 2 Data Showing Median Overall Survival Of 15.6 Months In Bria-IMT Study For Metastatic Breast Cancer, Comparing Favorably To 6.7-9.3 Months In Literature; No Drug-Related Discontinuations, And Ongoing Phase 3 Study...
BriaCell Announces Phase 2 Data Showing Median Overall Survival Of 15.6 Months In Bria-IMT Study For Metastatic Breast Cancer, Comparing Favorably To 6.7-9.3 Months In Literature; No Drug-Related Discontinuations, And Ongoing Phase 3 Study...
BriaCell宣佈Bria-IMt研究中2期數據顯示，乳腺癌轉移患者的中位總生存期爲15.6個月，與文獻中的6.7-9.3個月相比，結果較爲有利；無藥物相關的停用事件，並正在進行3期研究...
BriaCell Announces Phase 2 Data Showing Median Overall Survival Of 15.6 Months In Bria-IMT Study For Metastatic Breast Cancer, Comparing Favorably To 6.7-9.3 Months In Literature; No Drug-Related Discontinuations, And Ongoing Phase 3 Study Investigating Bria-IMT
BriaCell公佈的第二階段數據顯示，Bria-IMT轉移性乳腺癌研究的總存活率中位數爲15.6個月，與文獻中的6.7-9.3個月相比良好；沒有與藥物相關的停藥，正在進行Bria-IMT的3期研究
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。